Pyoderma Recruiting Phase 2 Trials for Baricitinib (DB11817)

Also known as: Dermatitis pyogenic / Dermatitis gangrenosa / Pyoderma (skin infection)

IndicationStatusPhase
DBCOND0014093 (Pyoderma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04901325Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)Treatment